Roche's immunotherapy Tecentriq gets European nod for breast cancer


ZURICH, Aug 29 (Reuters) - Roche's ROG.S Tecentriq won European approval to be used against tough-to-treat triple-negative breast cancer, helping the Swiss drugmaker's immunotherapy expand indications as it seeks to rival more-established medicines.

The European Commission approved Tecentriq with Abraxane for people with metastatic triple-negative breast cancer that tests positive for a protein believed to help the tumour evade attack by the body's immune system, Roche said on Thursday.

(Reporting by John Miller Editing by Tassilo Hummel)

((; +41 58 306 7734; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.